Maravai Lifesciences Holdings (MRVI) Cost of Revenue (2020 - 2026)

Maravai Lifesciences Holdings' Cost of Revenue history runs 7 years deep, the most recent figure standing at $32.1 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 17.86% year-over-year to $32.1 million in Q1 2026; TTM through Mar 2026 was $144.8 million, a 4.55% decrease from a year earlier, with the FY2025 full-year figure at $151.8 million, up 0.58% from the prior year.
• Cost of Revenue retreated to $32.1 million in Q1 2026 per MRVI's latest filing, from $37.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $53.3 million in Q4 2022 and bottomed at $32.1 million in Q1 2026.
• The 5-year median for Cost of Revenue is $37.5 million (2022), against an average of $38.4 million.
• Across the five-year window, Cost of Revenue soared 36.06% in 2022 and tumbled 34.07% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $53.3 million in 2022, then slumped by 34.07% to $35.1 million in 2023, then grew by 5.87% to $37.2 million in 2024, then dropped by 0.39% to $37.0 million in 2025, then fell by 13.2% to $32.1 million in 2026.
• Per Business Quant, the three latest MRVI Cost of Revenue figures stand at $32.1 million (Q1 2026), $37.0 million (Q4 2025), and $36.0 million (Q3 2025).